In addition, it was found that in NAFLD, osteoprotegerin could regulate liver lipid metabolism by targeting the ERK/PPARγ/CD36 pathway, and hypertension could be regulated by the ERK/PPARγ signal pathway in cardiovascular disease [59]. The gene discussed is PPARG; the disease is metabolic dysfunction-associated steatotic liver disease.